Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Assembly Biosciences's Enterprise Value is €-25.45 Mil.
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-51.62 Mil. Therefore, Assembly Biosciences's EV-to-EBIT ratio for today is 0.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Assembly Biosciences's Enterprise Value is €-25.45 Mil.
Assembly Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-51.29 Mil. Therefore, Assembly Biosciences's EV-to-EBITDA ratio for today is 0.50.
Assembly Biosciences Enterprise Value Historical Data
The historical data trend for Assembly Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Assembly Biosciences's Enterprise Value
For the Biotechnology subindustry, Assembly Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Enterprise Value falls into.
Assembly Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Assembly Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (FRA:V7B) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Assembly Biosciences's current Enterprise Value is €-25.45 Mil.
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.62 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Assembly Biosciences's current Enterprise Value is €-25.45 Mil.
Assembly Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.29 Mil.
Assembly Biosciences's current Enterprise Value is €-25.45 Mil.
Assembly Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Assembly Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Assembly Biosciences (FRA:V7B) Business Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:V7B has been successfully added to your 